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Pereira A, Palma dos Reis RP, Rodrigues R, Sousa AC,
Gomes S, Borges S, Ornelas I, Freitas AI, Guerra G, Henriques
E, Rodrigues M, Freitas S, Freitas C, Brehm A, Pereira D,
Mendonça MI. Association of ADAMTS7 gene polymorphism
with cardiovascular survival in coronary artery disease. Physiol
Genomics 48: 810 – 815, 2016. First published September 9, 2016;
doi:10.1152/physiolgenomics.00059.2016.—Recent genetic studies
have revealed an association between polymorphisms at the
ADAMTS7 gene locus and coronary artery disease (CAD) risk.
Functional studies have shown that a CAD-associated polymorphism
(rs3825807) affects ADAMTS7 maturation and vascular smooth mus-
cular cell (VSMC) migration. Here, we tested whether ADAMTS7
(A/G) SNP is associated with cardiovascular (CV) survival in patients
with established CAD. A cohort of 1,128 patients with angiographic
proven CAD, who were followed up prospectively for a mean fol-
low-up period of 63 (range 6–182) mo, were genotyped for rs3825807
A/G. Survival statistics (Cox regression) compared heterozygous
(AG) and wild-type (AA) with the reference homozygous GG. Ka-
plan-Meier (K-M) survival curves were performed according to
ADAMTS7 genotypes for CV mortality. Results showed that 47.3%
of patients were heterozygous (AG), 36.5% were homozygous for the
wild-type allele (AA) and only 16.2% were homozygous for the GG
genotype. During the follow-up period, 109 (9.7%) patients died, 77
(6.8%) of CV causes. Survival analysis showed that AA genotype was
an independent risk factor for CV mortality compared with reference
genotype GG (HR  2.7, P  0.025). At the end of follow-up, the
estimated survival probability (K-M) was 89.8% for GG genotype,
82.2% for AG and 72.3% for AA genotype (P  0.039). Carriage of
the mutant G allele of the ADAMTS7 gene was associated with
improved CV survival in patients with documented CAD. The native
overfunctional ADAMTS7 allele (A) may accelerate VSMC migra-
tion and lead to neointimal thickening, atherosclerosis progression and
acute plaque events. ADAMTS7 gene should be further explored in
CAD for risk prediction, mechanistic and therapeutic goals.
ADAMTS7 gene; coronary artery disease; single nucleotide polymor-
phism (SNP), cardiovascular survival
ADAMTS7 IS A MEMBER of a disintegrin and metalloprotease with
thrombospondin type 1 repeats (ADAMTS) family with pro-
teolytic activity against extracellular substrates, mainly extra-
cellular matrix proteins (1). The importance of ADAMTS
proteases is implicated in the establishment of tissue architec-
ture during development and in tissue degradation during
disease states such as cancer, Alzheimer’s and chronic inflam-
matory conditions (20).
A recent study revealed the first firm evidence that
ADAMTS7 plays a proatherogenic role likely through the
promotion of vascular smooth muscular cell (VSMC) migra-
tion by degrading its primary substrate, the cartilage oligo-
meric matrix protein (COMP), and thus promoted neointima
formation following vascular mechanical injury (18). More-
over, in vitro studies have shown that VSMCs produce COMP,
which inhibits VSMC migration (18). Consistently, genetic
deletion of ADAMTS7 protects mice from atherosclerosis by
reducing VSMC migration (4). Since VSMC migration is a
very relevant process for plaque formation and stability, it is
likely that ADAMTS7 may play a role in the development of
atherosclerosis, the major cause of coronary artery disease
(CAD).
In fact, three independent genome-wide association studies
have recently identified the ADAMTS7 in the 15q24.2 chro-
mosome, a novel locus for the development of coronary ath-
erosclerosis (6, 14, 16). The lead CAD-associated SNP was
rs3825807, a nonsynonymous polymorphism, with an adenine
(A) to guanine (G) change, resulting in a serine-to-proline
substitution in the prodomain of ADAMTS7 (16). Previous
results suggest that this polymorphism has an effect on
ADAMTS7 maturation, COMP degradation, and VSMC mi-
gration and thus is associated with atherosclerosis (13).
We aimed to examine whether the carriage of the
ADAMTS7 rs3825807 A/G polymorphism plays a role in the
cardiovascular (CV) survival, in a cohort of patients with
significant angiographic coronary artery disease.
MATERIALS AND METHODS
Study population. A prospective study was performed with a cohort
of 1,128 individuals (mean age 53.3  7.9 yr, 79.6% men) admitted
for coronary angiography due to angina and clinical suspicion of
ischemic heart disease from either sex that gave written informed
consent. The study was approved by the Funchal Hospital Ethics
Committee.
Subjects were primary local residents, and this population is ge-
netically a Caucasian south European sample. Nonresidents were not
considered for this study.
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Determination of presence and severity of CAD was made by the
hemodynamic laboratory staff that included a dedicated intervention
cardiologist. Angiographically proven CAD was considered signifi-
cant if 1 coronary lesions of 70% stenosis in 1 major coronary
artery or its primary branch. Absent or nonsignificant CAD was
excluded from this study. Index angiography occurred between 2008
and 2013.
This cohort was followed until death or December 2014 [mean
follow-up period of 63 mo (range 6–182 mo)]. Each subject was
followed up at the outpatient clinic according to the angiography date,
and data concerning new hospital admissions or angiograms were
collected from the clinical files of patients.
In the case of extrahospital death, death cause was collected
consulting the public death report and by family telephone survey.
The causes of CV death were determined according to the Interna-
tional Classification of Disease, 10th revision, clinical modification
diagnostic criteria. Cardiovascular death included CAD and cerebro-
vascular disease.
Follow-up using the database and direct contact with patients or
families allowed for 100% assessment of survival within this cohort.
Data collection. Data were collected from all subjects in a stan-
dardized file comprising demographic and clinical characteristics and
traditional risk factors (sex, age, sedentary lifestyle, smoking habits,
arterial hypertension, diabetes, dyslipidemia, body mass index, heart
rate and pulse wave velocity). The definition of conventional CV risk
factors was based on the standard criteria, as previously reported (3,
5, 6a, 7, 12).
Biochemical analysis. Blood samples were extracted after 14–16 h
fasting. Biochemical analyses were performed in the central labora-
tory of the hospital, according to the usual techniques.
To determine total cholesterol and triglycerides, blood samples
were placed in dry tubes and centrifuged a half-hour later at 3,500 g
and subsequently quantified by an enzymatic technique with a Hitachi
911 auto analyzer. Biochemical markers such as lipoprotein-a, apoli-
poprotein B (Apo B), and high sensitivity C-reactive protein (hs-CRP)
were quantified by nephelometry on a Behring BN 100 automatic
system. Homocysteine was measured by fluorescence polarized im-
munoassay using an Abbot IMX automatic device. To measure
fibrinogen, samples placed in a tube containing sodium citrate, and
measurements were taken with a Behring BCS automatic analyzer.
Genotype analyses. Genomic DNA was extracted from 80 ml of
peripheral blood using a standard phenol-chloroform method (Qiagen,
Hilden, Germany).
To identify the ADAMTS7 rs3825807 A/G genotypes, a TaqMan
allelic discrimination assay (Applied Biosystems) was performed
using labeled probes and primers pre-established by the supplier
(TaqMan SNP Genotyping Assays, Applied Biosystems).
The genotyping reaction was amplified and detected on a
StepOnePlus Real-Time PCR, and genotypes were determined by
Table 1.
Variables Total (n  1,128) Survivors (n  1,019) Deaths (n  109) Cardiovascular Deaths (n  77) P1 P2
Male (%) 898 (79.6) 808 (79.3) 90 (82.6) 64 (83.1) 0.420 0.429
Age, yr 53.3  7.9 53.1  8.0 55.5 7.6 55.5  8.2 0.003 0.015
Sedentarism (%) 718 (63.7) 638 (62.6) 80 (73.4) 55 (71.4) 0.026 0.142
Smoking (%) 511 (45.3) 463 (45.4) 48 (44.0) 34 (44.2) 0.780 0.834
Hypertension (%) 819 (72.6) 745 (73.1) 74 (67.9) 49 (63.6) 0.245 0.067
PWV, m/s 8.7  2.0 8.6  1.9 9.0 2.1 8.9  2.3 0.058 0.261
Diabetes (%) 387 (34.3) 336 (33.0) 51 (46.8) 35 (45.5) 0.004 0.033
Dyslipidemia (%) 1,057 (93.7) 952 (93.4) 105 (96.3) 74 (96.1) 0.235 0.369
BMI, kg/m2 28.6  4.3 28.6  4.2 28.6 4.7 28.7  4.6 0.994 0.827
Heart rate, bpm 69.4  12.4 68.9  12.1 73.7 14.6 74.7  13.9 0.001 0.0001
P1 compares patients dying from any cause with survivors, and P2 compares patients dying from cardiovascular causes with others. PWV, pulse wave velocity;
BMI, body mass index. Continuous variables are presented as means  SD; Statistically significant for P  0.05.
Table 2.
Variables Total (n  1,128) Survivors (n  1,019) Deaths (n  109) Cardiovascular Deaths (n  77) P1 P2
Hemoglobin, g/dl 14.6 14.6 14.8 14.9 0.889 0.915
(8.6–18.2) (8.6–18.2) (10.9–18.0) (11.0–17.6)
Platelets, 103/l 214.5 214.0 224.0 227.0 0.106 0.048
(61.0–893.0) (61.0–893.0) (116.0–533.0) (116.0–533.0)
Leukocytes, 103/l 7.0 7.0 7.4 7.8 0.022 0.006
(3.4–24.6) (3.4–24.6) (4.1–13.3) (4.4–12.4)
Fibrinogen, mmHg 383.0 382.5 399.4 383.0 0.096 0.449
(91.0–832.0) (91.0–715.0) (153.3–832.0) (153.3–832.0)
Homocysteine, mol/l 12.4 12.3 12.8 12.7 0.017 0.044
(4.6–220.2) (4.6–220.2) (5.9–48.7) (5.9–48.7)
Lp(a), mg/dl 19.9 19.3 26.0 23.4 0.065 0.489
(1.9–241.0) (1.9–241.0) (1.9–219.0) (1.9–191.5)
Apo B, mg/dl 96.4 95.9 101.5 102.0 0.007 0.012
(4.9–256.9) (4.9–256.9) (20.1–181.0) (20.1–173.0)
Triglycerides, mg/dl 143.0 143.0 149.0 153.0 0.123 0.110
(31.0–2,500.0) (31.0–2500) (44.0–608.0) (44.0–571.0)
Glucose, mg/dl 106.0 106.0 116.5 118.0 0.0001 0.0001
(53.0–458.0) (53.0–458.0) (67.0–393.0) (67.0–393.0)
hs-CRP, mg/dl 0.24 0.23 0.36 0.3 0.005 0.083
(0.01–24.8) (0.01–24.8) (0.02–15.6) (0.02–7.9)
P1 compares patients dying from any cause with survivors, and P2 compares patients dying from cardiovascular causes with others. Lp(a), lipoprotein (a); Apo
B, apolipoprotein B; hs-CRP, high sensitivity C reactive protein. Values are medians (minimum - maximum); statistically significant for P  0.05.
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using the 7300 System SDS Software without any prior knowledge of
individual clinical data (Applied Biosystems, Foster City, CA).
Statistical analyses. Deviation from Hardy-Weinberg equilibrium
for genotypes at individual locus was assessed using the 2-test.
Comparisons of characteristics of CV death and survivors were
analyzed by 2 for categorical variables, and Student’s t- or Mann-
Whitney test was performed for continuous variables as appropriate.
Genotypic frequencies were determined from observed counts and
compared by 2 analysis. Heterozygous (AG) or homozygous wild-
type (AA) carriers were compared with noncarriers (GG) with sur-
vival statistics.
Multivariable Cox proportional-hazard regression analyses were
used to examine the CV death between genotypes of ADAMTS7
variants, using GG as reference class (genotype model). Hazard ratios
and the multiple variable predictive values were determined, condi-
tioned on seven other major CAD risk factors: age, sex, smoking
status, diabetes, hypertension, dyslipidemia, and renal failure. The
critical value for entering and excluding variables in the model was set
at P  0.10. Multivariable Cox proportional-hazard regression anal-
yses also addressed the all-cause mortality including the same set of
covariates.
Kaplan Meyer survival function with Log-rank statistics was tested
to predict the value of the ADAMTS7 genotypes for CV mortality.
Statistical analyses were performed using Statistical Package for
the Social Sciences Software version 19.0 (IBM, Armonk, NY).
RESULTS
A total of 1,128 patients (mean age 53.3  7.9 yr, 79.6%
men) with documented CAD entered this study, during a mean
follow-up period of 63 mo (range 6–182 mo). Baseline and
biochemical characteristics of the studied population are shown
in Table 1 and Table 2, respectively.
Of entered patients, 109 (9.7%; mean age 55.5  7.6 yr,
82.6% men) died during the follow-up period and 77 (6.8%,
mean age 55.5  8.2 yr, 83.1% men) of CV causes. Nonsur-
vivors were older at baseline, more sedentary, had more dia-
betes and higher heart rates than survivors, with statistical
significance (P  0.05) (Table 1). Additionally, leukocytes,
homocysteine, apo B levels, glucose and hs-CRP were higher
in patients who died during the follow-up than in survivors
(Table 2).
ADAMTS7 genotypic distributions are shown in Table 3 for
all patients, namely, survivors, those dying of any cause, and
those dying of a CV cause. The distribution of alleles was in
Hardy-Weinberg equilibrium (P  0.890). Genotypic analysis
revealed that 47.3% of patients were heterozygous (AG),
36.5% were homozygous for the wild-type allele (AA), and
only 16.2% were homozygous for the GG genotype. The
proportion of alleles present in the cohort was 60.2% for the
wild-type allele (A) and 39.8% for the G allele. CV deaths
occurred in 49.4% of the carriers of the wild-type ADAMTS7
AA, while 7.8% were individuals with the polymorphic GG
genotype (Table 3).
In multiple variable Cox regression analysis (Table 4),
including age, sex, smoking status, diabetes, history of hyper-
tension and of dyslipidemia, renal failure, and genetic variant
(ADAMTS7), only age [hazard ratio (HR)  1.051, P 
0.001], hypertension (HR  0.634, P  0.063), and
ADAMTS7 AA genotype carriers (HR  2.681, P  0.025)
were selected as independent predictors of CV mortality
(Table 4).
Kaplan-Meier survival-time plot for CV death by
ADAMTS7 genotype is shown in Fig. 1. A significant differ-
ence in survival by ADAMTS7 genotype was observed (log-
rank statistic 6.48, P  0.039). At the end of follow-up period,
the survival probability was 89.8% for the GG genotype
carriers, 82.2% for heterozygote individuals (AG) and 72.3%
for the wild-type (AA). Within each ADAMTS7 genotype,
3.3% (6/183) of events (CV deaths) occurred for patients
carrying the polymorphic genotype (GG), 6.2% (33/533)
among the heterozygote (AG) carriers, and 9.2% (38/412)
occurred for patients who had the wild-type genotype (AA) as
shown in Fig. 1.
Table 3.
Group Wild Type (AA) Heterozygote (AG) Homozygote (GG) WT (A) Allele Variant (G) Allele
A: All patients/All deaths
Survivors (1,019) 364 (35.7%) 484 (47.5%) 171 (16.8%) 1,212 (59.5%) 826 (40.5%)
Deaths (109) 48 (44.0%) 49 (45.0%) 12 (11.0%) 145 (66.5%) 73 (33.5%)
Total (1,128) 412 (36.5%) 533 (47.3%) 183 (16.2%) 1,357 (60.2%) 899 (39.8%)
B: CV deaths/CV survivors
No CV death (1,051) 374 (35.6%) 500 (47.6%) 177 (16.8%) 1,248 (59.4%) 854 (40.6%)
CV deaths (77) 38 (49.4%) 33 (42.9%) 6 (7.8%) 109 (70.8%) 45 (29.2%)
Total (1,128) 412 (36.5%) 533 (47.3%) 183 (16.2%) 1,357 (60.2%) 899 (39.8%)
For A, death by genotype contingency tables gives P  0.134 (2). For B, CV death by genotype gives P  0.021 2), P  0.017 (likelihood ratio) or P 
0.006 (linear-by-linear association).CV, cardiovascular; WT, wild type.
Table 4.
Variables B SE Wald df Hazard Ratio (CI 95%) P Value
Age 0.049 0.016 10.131 1 1.051 (1.019–1.083) 0.001
AHT 0.455 0.245 3.462 1 0.634 (0.393–1.025) 0.063
ADAMTS7 5.481 2 0.065
AG 0.690 0.444 2.412 1 1.993 (0.835–4.760) 0.120
AA 0.986 0.440 5.016 1 2.681 (1.131–6.353) 0.025
Using forward Wald conditional Cox regression method (SPSS v 19.0), entering age (yr), male sex, diabetic status, history of hypertension, history of
dyslipidemia, renal failure, smoking and genetic variant ADAMTS7. P value to exclude variables was 0.10. B, beta coefficient; CI, 95% confidence interval.
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A second Cox regression model, adjusted for the same
covariates, was performed for predicting all-cause mortality, as
shown in Table 5. During the follow-up period, the only
independent predictors of all-cause mortality were age (HR
1.05 P  0.0001), Diabetes (HR  1.469, P  0.05), and
smoking habit (HR  1.58, P  0.026). Neither carriage of
homozygous (AA) nor heterozygous (AG) genotypes were
independent predictors of all-cause mortality (HR  1.424,
P  0.276, HR  1.604, P  0.147 respectively) (Table 5).
DISCUSSION
In our study, patients with angiographically documented
CAD who were carriers of the polymorphic G variant of
ADAMTS7 gene had increased survival from CV causes. For
instance, at the end of the follow-up period, patients with
ADAMTS7 GG showed approximately three times fewer
events of CV mortality in relation to AA carriers.
We consider that the carriers of the G allele had reduced
migratory ability with lower atherosclerosis progression and
severity, reduced proteinases secretion to influence the stability
of the complex plaque, and therefore better prognostic than
patients carrying the wild-type A of the ADAMT7 gene.
Similarly, Pu and colleagues (13), observed an inverse
association between the ADAMTS7 rs3825807 GG genotype
and atherosclerosis, this being the genotype associated with
lower carotid atherosclerosis prevalence and severity (score).
The same study demonstrated that VSMCs of the protective
GG genotype had decreased migratory activity compared with
those with the AA genotype, and conditioned media of VSMCs
of the GG contained less of the cleaved form of COMP, an
ADAMTS7 substrate that had been shown to be produced by
VSMCs and inhibit its migration (13). Also, You et al. (19)
recently demonstrated a strong and direct association between
the proportion of CAD patients with three-vessel disease and
increasing ADAMTS7 rs3825807 gene dosage of the risk
variant (A). This condition was investigated in the cohort of
our study, but no significant association was found between
AA genotype and most severe atherosclerosis (three-vessel
disease), although there was a strong trend (data not shown).
However, to date, an association between the CAD progno-
sis and this polymorphism has not yet been found. As far as we
know, this study is the first attempt to establish this association
in a cohort of south European descendent.
Previously, investigation of the physiological roles of
ADAMTS7 has largely focused on its association with the
pathogenesis of arthritis and disk diseases (6a). ADAMTS
structure contains the thrombospondin type-1 repeats and acts
as a negative regulator of endplate chondrocyte differentiation
because it downregulates the expression of collagen type II,
collagen type X, and SOX9, which are early and late marker
genes for chondrogenesis (11). Furthermore, suppression of
ADAMTS7 expression in human chondrocytes markedly pre-
vents COMP degradation (9). ADAMTS7 mRNA is found in
normal human bone, cartilage, synovia, tendons, spleen, heart,
and brain, as well as in the meniscus, skeletal muscle, and fat
at lower levels (10). However, the physiological implications
of this widespread tissue expression of ADAMTS7 remain to be
determined. Furthermore, cumulative evidence has demon-
strated that ADAMTS7 facilitates VSMC migration and neoin-
tima formation through degradation of vascular COMP (18).
Consistently, genetic deletion of ADAMTS7 reduces neointimal
thickening after wire injuries (4).
In our study, it’s interesting to note that besides ADAMTS7
AA genotype, the hypertension status and age were indepen-
dent predictors of CV mortality; being elderly and lower
tensional status both correlated with CV death. The indepen-
dence of CV death predictors from other traditional risk factors
like dyslipidemia, diabetes, and renal failure emphasizes the
ADAMT7 gene’s mechanistic role being associated with vas-
cular cleavage and migration of VSMCs not currently covered
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Fig. 1. The log-rank statistic was 6.480, P 
0.039. There are 6 events (3.3%) among 183
patients carrying the homozygote, 33 events
(6.2%) among the patients who had the het-
erozygote type, and 38 events (9.2%) among
the patients who had the wild type.
Table 5.
Variables B SE Wald df Hazard ratio (CI 95%) P Value
Age 0.050 0.014 13.405 1 1.051 (1.023–1.080) 0.000
Diabetic status 0.384 0.197 3.826 1 1.469 (0.999–2.159) 0.050
Smoking 0.456 0.204 4.973 1 1.578 (1.057–2.355) 0.026
Using forward Wald conditional Cox regression method (SPSS v 19.0), entering age (yr), male sex, diabetic status, history of hypertension, history of
hyperlipidemia, renal failure, smoking, and genetic variant ADAMTS7. P value to exclude variables was 0.10. B, beta coefficient; CI, 95% confidence interval.
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by updated therapies including statins, ACE inhibitors, angio-
tensin-aldosterone-antagonists, B-blockers, and antidiabetic
medication. Monoclonal antibodies targeting several ADAMTS
gene family members are on the way in several clinical
scenarios, and the ADAMTS7 gene seems a highly favorable
candidate for use against for CAD because of the gene’s
already established association with the development of CAD.
Future genetic studies in CAD disease should focus on disease
progression and prognosis rather than disease development. So
far, established risk factors of atherosclerosis are not able to
fully account for CV death due to different pathophysiological
mechanisms involved into plaque formation and plaque events.
CV death might be associated with the critical mechanisms of
plaque stabilization/thrombosis and arrhythmia in CAD pa-
tients and gene associated with vascular migration/stabilization
are promising targets (14).
Nevertheless, in our study the AA genotype was found to
be unassociated with all-cause mortality and associated only
with CV mortality, which strengthens the hypothesis that
ADAMTS7’s being a regulator of the gene maturation, COMP
cleavage, and VSMC migration would translate into fewer CV
events, including CV death in patients with a reduced function
of the ADAMTS gene (G) variant.
Further research in this area could lead to personalized
medicine based on identification of ADAMTS7 genetic vari-
ants in patients with atherosclerosis who could benefit from
strategies targeting this proteolytic pathway (2).
Study Strengths and Limitations
Very few studies have yet addressed common gene variants
and outcomes and long-term prognosis, and even the 9p21
gene failed to demonstrate consistent association with long-
term myocardial infarction and CV mortality (17). No report
on the specific association of ADAMTS7 gene variants with
CV mortality in CAD patients has been published.
However, this study is only moderate in size, and the number
of events in the follow-up is limited, so that the confidence
intervals for CV survival are quite broad.
A significant limitation of the study was the lack of ejection
fraction data at admission for determining the relative protec-
tive effect of the variant as a function of the ejection fraction.
Patients deceived during the coronary angiogram were also
excluded from our study. Those patients probably had severe
atherosclerotic coronary disease, and their DNA sample would
be useful to enlarge our knowledge of this variant role in CV
death. Expression studies of these ADAMTS7 gene variants on
the arterial wall of the atherosclerotic plaque or thrombus
would also further information from animal studies already
published.
In conclusion: Our study emerges as a novel finding in a
south European population and provides new evidence impli-
cating ADAMTS7 with CAD prognosis. Its spectrum of interest
as a therapeutic target may grow once its association with
outcomes and CV mortality is clarified. Our results, although
promising, should be amplified in larger and long-term studies
that focus on CV prognosis rather than disease development. If
validated, they suggest that ADAMTS7 genotyping may pro-
vide useful information for prognosis and survival in CAD
patients.
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